Lamivudina Aurobindo Italia (Lamivudine)

Lamivudine is a nucleoside analogue that is converted inside cells to its active triphosphate form. This active metabolite competes with natural nucleosides for incorporation into viral DNA by reverse transcriptase. Once incorporated, it terminates the DNA chain, preventing further viral replication of HIV and hepatitis B virus.

The specific dosing regimen for Lamivudina Aurobindo Italia is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other individual factors. Healthcare professionals should follow current clinical guidelines and adjust the dose as needed for each patient.

Lamivudine is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy if the potential benefit outweighs any possible risk. Lamivudine is excreted in breast milk, so a risk‑benefit assessment should be performed before breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lamivudina Aurobindo Italia. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for synergistic effect. Compared with older NRTIs such as zidovudine, lamivudine generally has a more favorable safety profile, fewer mitochondrial toxicities, and is active against both HIV and hepatitis B, making it a versatile component of combination regimens.

Lamivudina Aurobindo Italia should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescribing clinician. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed to maintain consistent drug levels.

Serious adverse events, although rare, include lactic acidosis, severe hepatomegaly with steatosis, pancreatitis, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Lamivudina Aurobindo Italia should be avoided in individuals with known hypersensitivity to lamivudine or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment, mitochondrial disorders, or those who are pregnant without a clear clinical indication.